On December 1, 2025, the European Union (EU) Observatory for Nanomaterials (EUON) announced the availability of a report analyzing the applications of nano-enabled textiles...

In January 2026, the Institute of Technology Assessment of the Austrian Academy of Sciences published a NanoTrust Dossier entitled...

This week I had the pleasure of speaking with Ryan N. Schmit, Of Counsel with B&C, and Senior Regulatory Consultant with The Acta Group (Acta®).

On August 1, 2025, Senators Elissa Slotkin (D-MI), Amy Klobuchar (D-MN), Joni Ernst (R-IA), and Pete Ricketts (R-NE) reintroduced the bipartisan Biomanufacturing and Jobs Act (S. 2654).

The European Chemicals Agency (ECHA) announced on October 9, 2025, that at its October 7-8, 2025, meeting, the Member State Committee (MSC) agreed to identify 1,1′-(ethane-1,2-diyl)bis[pentabromobenzene]...

On February 10, 2026, EPPA, a Brussels-based regulatory and public affairs consultancy, will hold a webinar on "Shaping the ETS/CBAM Reforms: Strategic Insights for Energy-Intensive industries."

The House Energy and Commerce Subcommittee on Environment will hold a legislative hearing on January 22, 2026, entitled "Chemicals in Commerce: Legislative Proposal...

This week, I discuss with my colleague, Kelly N. Garson, a Senior Associate here at B&C and Regulatory Consultant for The Acta Group (Acta®), B&C's consulting affiliate...

The Particles Platform, an informal alliance of European Union (EU) industry associations representing manufacturers of materials in the form of particles, including poorly soluble low toxicity particles (PSLT)...

A few months ago, I recorded a podcast with my colleagues, Carla N. Hutton, Senior Regulatory Analyst for B&C, and Dr. Richard E. Engler, Director of Chemistry for B&C and The Acta Group...

This week, I had the pleasure of speaking with Dr. Richard E. Engler, Director of Chemistry for B&C and The Acta Group (Acta®), our consulting affiliate, and Ryan N. Schmit, Of Counsel with B&C...

The American Sustainable Business Network (ASBN) announced on April 14, 2026, that it is inviting all businesses, brands, retailers, ingredient suppliers, institutional purchasers, investors...

On June 6, 2025, the U.S. Department of Agriculture's (USDA) Animal and Plant Health Inspection Service (APHIS) announced that it has prepared a revised draft environmental impact statement...

The U.S. Environmental Protection Agency plays a crucial role in protecting public health from deadly pathogens like Ebola and Hantavirus through its regulatory authority under FIFRA. Regulatory experts Dana S. Lateulere and James V. Aidala discuss how EPA reviews, approves, and regulates pathogen-combating products, and why these public health protections are more critical than ever.

The Organisation for Economic Co-operation and Development (OECD) has published a September 2025 document entitled Guidance Document on Assessing the Apparent Accumulation Potential of Nanomaterials.

The Physicians Committee for Responsible Medicine and the International Collaboration on Cosmetics Safety are launching a webinar series to address the complex regulatory landscape surrounding sunscreen testing and development. With conflicting requirements between countries—some mandating animal-free testing while others still require it—the initiative seeks to identify practical, animal-free assessment methods that improve predictivity for UV-filter safety evaluation.

The International Organization for Standardization (ISO) recently published two standards for graphene-related two-dimensional (2D) materials...

The National Academies of Sciences, Engineering, and Medicine (NASEM) will hold a webinar on July 17, 2025, on "Nanotechnology R&D Infrastructure: Then and Now." NASEM states that...

On January 29, 2026, Senator Tom Cotton (R-AR) introduced the Biosecurity Modernization and Innovation Act of 2026 (S. 3741) to establish a federal biosecurity framework.

The Senate Finance Subcommittee on Health Care will convene to examine how biotechnology can strengthen America's healthcare infrastructure and address critical challenges in medical innovation. Expert witnesses from leading research institutions and academic medical centers will provide testimony on advancing biotechnology solutions for infectious diseases, antibiotic resistance, and healthcare resilience.